DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury. (Q53797319)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 February 2016

Language	Label	Description	Also known as
English	DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury.	scientific article published on 15 February 2016

Statements

scholarly article

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury. (English)

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

author name string

Jee Eun Lee

1

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Jung Eun Kim

2

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Mi Hwa Lee

3

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Hye Kyoung Song

4

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Jung Yeon Ghee

5

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Young Sun Kang

6

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Hye Sook Min

7

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Hyun Wook Kim

8

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Jin Joo Cha

9

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Jee Young Han

10

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Sang Youb Han

11

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Dae Ryong Cha

12

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

publication date

15 February 2016

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Laboratory Investigation

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

96

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

547-560

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

5

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

https://scigraph.springernature.com/pub.10.1038/labinvest.2016.34

0 references

Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

The effect of glucagon-like peptide 1 on cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Podocyte loss and progressive glomerular injury in type II diabetes

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Expanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Prevention of obesity-induced renal injury in male mice by DPP4 inhibition

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Adriamycin nephropathy: a model of focal segmental glomerulosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Molecular mechanisms of diabetic renal hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Cellular and molecular mechanisms of proteinuria in diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2016.34

21 January 2018

Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin

1 reference

https://pubmed.ncbi.nlm.nih.gov/26878135

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1

1 reference

https://pubmed.ncbi.nlm.nih.gov/26878135

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/26878135

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals

1 reference

https://pubmed.ncbi.nlm.nih.gov/26878135

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dipeptidyl peptidase IV (DDP IV) in NASH patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26878135

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in Finnish patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26878135

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

1 reference

https://pubmed.ncbi.nlm.nih.gov/26878135

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/26878135

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/26878135

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26878135

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LABINVEST.2016.34

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

19 May 2018

http://europepmc.org/abstract/MED/26878135

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53797319&oldid=1450899736"